Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant Docetaxel, Carboplatin, and Bevacizumab in Early Stage NSCLC
NCT00293332Phase 2Terminated
- Sponsor
- University of California, San Francisco
- Start
- Dec 2005
- Primary completion
- Mar 2007
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bevacizumab in non-small cell lung cancer (NSCLC), sponsored by University of California, San Francisco. Primary endpoint: Clinical response rate by CT scan. Started Dec 2005; status: terminated.
02
Drugs
bevacizumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT00293332.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00293332.